Cardiovascular risk reduction: the future of cholesterol lowering drugs

Highlights • Hyperlipidemia increases the risk of atherosclerotic cardiovascular disease. • Lowering LDL-C, especially with statins, decreases cardiovascular risk. • Statins, bile acid sequestrants, ezetimibe, niacin, mipomersen, and lomitapide lower LDL-C. • Anti-PCSK9 therapy is a new treatment th...

Full description

Saved in:
Bibliographic Details
Published in:Current opinion in pharmacology 2016-04, Vol.27, p.62-69
Main Authors: Bou Malham, Sarah, Goldberg, Anne Carol
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - therapeutic use
Anticholesteremic Agents - therapeutic use
Cardiovascular Diseases - blood
Cardiovascular Diseases - drug therapy
Cardiovascular Diseases - metabolism
Cholesterol - blood
Cholesterol, LDL - blood
Humans
Internal Medicine
Medical Education
Proprotein Convertase 9 - metabolism
Risk Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Hyperlipidemia increases the risk of atherosclerotic cardiovascular disease. • Lowering LDL-C, especially with statins, decreases cardiovascular risk. • Statins, bile acid sequestrants, ezetimibe, niacin, mipomersen, and lomitapide lower LDL-C. • Anti-PCSK9 therapy is a new treatment that lowers LDL-C substantially. • Early LDL-C lowering could modify the course of atherosclerotic disease.
ISSN:1471-4892
1471-4973
DOI:10.1016/j.coph.2016.01.007